FY2025 EPS Estimates for Biohaven Cut by Cantor Fitzgerald

Biohaven Ltd. (NYSE:BHVN) – Equities research analysts at Cantor Fitzgerald dropped their FY2025 earnings per share (EPS) estimates for Biohaven in a research note issued on Tuesday, March 4th. Cantor Fitzgerald analyst C. Duncan now forecasts that the company will post earnings of ($6.80) per share for the year, down from their previous estimate of ($6.05). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Biohaven’s current full-year earnings is ($8.90) per share.

Other equities analysts have also issued reports about the stock. TD Cowen raised their target price on shares of Biohaven from $55.00 to $75.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. HC Wainwright reaffirmed a “buy” rating and set a $54.00 price target on shares of Biohaven in a research report on Tuesday. JPMorgan Chase & Co. dropped their price target on Biohaven from $72.00 to $68.00 and set an “overweight” rating on the stock in a research note on Wednesday. Royal Bank of Canada reiterated an “outperform” rating and set a $61.00 price objective on shares of Biohaven in a report on Tuesday. Finally, Deutsche Bank Aktiengesellschaft began coverage on shares of Biohaven in a report on Tuesday, February 11th. They issued a “buy” rating and a $65.00 target price for the company. Fourteen analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Biohaven has an average rating of “Buy” and an average price target of $62.77.

Biohaven Price Performance

BHVN stock opened at $30.98 on Thursday. Biohaven has a fifty-two week low of $26.80 and a fifty-two week high of $62.21. The business’s fifty day moving average price is $38.07 and its two-hundred day moving average price is $42.66. The stock has a market capitalization of $3.13 billion, a price-to-earnings ratio of -3.31 and a beta of 1.27.

Biohaven (NYSE:BHVN) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($1.85) EPS for the quarter, missing analysts’ consensus estimates of ($1.56) by ($0.29).

Institutional Investors Weigh In On Biohaven

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. SpiderRock Advisors LLC purchased a new stake in shares of Biohaven during the third quarter worth approximately $620,000. Citigroup Inc. boosted its position in Biohaven by 125.8% in the 3rd quarter. Citigroup Inc. now owns 119,905 shares of the company’s stock valued at $5,992,000 after buying an additional 66,801 shares during the period. Y Intercept Hong Kong Ltd acquired a new stake in Biohaven in the 3rd quarter valued at about $1,339,000. JPMorgan Chase & Co. raised its holdings in Biohaven by 85.4% in the third quarter. JPMorgan Chase & Co. now owns 809,448 shares of the company’s stock valued at $40,448,000 after acquiring an additional 372,737 shares in the last quarter. Finally, XTX Topco Ltd lifted its position in shares of Biohaven by 278.5% during the 3rd quarter. XTX Topco Ltd now owns 32,510 shares of the company’s stock worth $1,625,000 after purchasing an additional 23,921 shares during the last quarter. Institutional investors and hedge funds own 88.78% of the company’s stock.

Insiders Place Their Bets

In other Biohaven news, Director John W. Childs purchased 29,000 shares of Biohaven stock in a transaction dated Monday, December 30th. The shares were acquired at an average cost of $35.94 per share, with a total value of $1,042,260.00. Following the completion of the transaction, the director now owns 2,368,741 shares in the company, valued at approximately $85,132,551.54. This trade represents a 1.24 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 16.00% of the stock is owned by insiders.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.